An interventional study of MCT Diet in Thoracic Neoplasms, sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Lung resection, a critical treatment for various thoracic diseases, including lung cancer, often necessitates prolonged hospitalization due to rare but severe postoperative complications such as chyle leaks, with an occurrence of 0.25%-3%, prolonging chest drainage, and delaying recovery. Therefore, effective postoperative care is essential for optimizing outcomes, reducing complications, and expediting recovery.
Recent studies have highlighted the significant potential of medium-chain triglyceride (MCT) diets, owing to their unique absorption pathway and metabolic properties. MCT contains mainly medium-chain fatty acids (MCFA), which is absorbed in the intestine and transported to the liver via the portal system instead of the lymphatic system. This helps to bypass the lymphatic system, thereby reducing the volume of lymph. MCFAs also provide better energy utilization in stressed condition since it does not require carnitine shuttle upon metabolism, which is beneficial to post-operation recovery.
Several studies have demonstrated the benefits of MCT diets in managing chyle leaks and supporting gastrointestinal recovery, particularly in conditions that strain the lymphatic system. For instance, short-term MCT-enriched diets have been associated with improved post-operation recovery of gastrointestinal, hepatic and renal functions, reduced total chest drainage volumes, and shorter hospital stay when compared to regular diet groups.
Patients with post-operative chyle leak following thoracic surgery are often given an MCT diet to reduce chest drain volume and hence shorten hospital stay. Based on the successful use of MCT diet on patients with chyle leak after lobectomy, it is hypothesized that patients with chylothorax provided with post-operative MCT diet can also shorten hospital stay by decreasing chest drainage. Therefore, a prospective and randomized trial is designed to investigate how post-operative MCT diet in lung resection patients without chylothorax may affect hospital stay and post-operative recovery.
This study is a single-center, prospective, randomized trial designed to investigate how a post-operative diet enriched with MCT affects recovery in patients undergoing video-assisted thoracic surgery (VATS). Medical students from the Chinese University of Hong Kong, under the supervision of the principal investigator, will conduct the study, including obtaining consent and collecting data. Experienced surgeons at the Prince of Wales Hospital will perform the VATS procedures.
2.2 Hypotheses
115 studies on the registry are indexed under Thoracic Neoplasms; 30 are open to participants now.
This study's planned enrollment of 210 is above the median of 61 across 86 interventional studies indexed under Thoracic Neoplasms.
Browse Thoracic Neoplasms studies →Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General Inclusion Criteria for All procedures:
Project-specific Criteria:
1. Patients performed lobectomy with lymph node dissection
Exclusion Criteria:
Patient general exclusion criteria:
Project-specific Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the control group will receive a standard hospital diet consistent with routine postoperative nutritional care after lobectomy with lymph node dissection. This diet does not include medium-chain triglyceride (MCT) supplementation and serves as a comparator to evaluate the effects of the MCT diet on postoperative recovery
Patients will receive a medium-chain triglyceride (MCT)-enriched diet during their hospital stay following lobectomy with lymph node dissection. The MCT diet is administered as part of the postoperative nutritional regimen to evaluate its impact on recovery outcomes
Dietary Supplement: MCT Diet
Participants will receive a medium-chain triglyceride (MCT) diet during their hospital stay and for two weeks following discharge. This aims to evaluate the effects of continued MCT dietary supplementation on postoperative recovery outcomes after lobectomy with lymph node dissection
Dietary Supplement: MCT Diet
MCT diet for patients following lung resection
hospital length of stay (LOS)
hospital length of stay (LOS), which is hypothesized to be reduced following the administration of an MCT diet. Currently, patients undergoing lobectomy using VATS have a median LOS of approximately 3-4 days. The study aims to investigate whether MCT diet interventions can reduce this to 2 days, representing a 30% reduction in hospital stay.
Time frame: From the end of the lung resection procedure until the time of patient discharge, assessed up to 7 days post-surgery
Total Chest Drain Output (mL)
Chest drain output indirectly reflects recovery status. The total chest drain output will be measured using the Medela digital chest drainage system, which is routinely used for patients undergoing lobectomy. Compared to manual drainage system, this system allows more precise monitoring of fluid output. This information will help evaluate the overall impact of the MCT diet on postoperative recovery, particularly in reducing fluid drainage.
Time frame: From the end of the lung resection procedure until the time of chest drain removal assessed up to 7 days post-surgery
Patient Satisfaction and Tolerability
Patient-reported outcomes will be assessed using a quality of life (QoL) questionnaire, which is an established tool for evaluating recovery after surgery. The questionnaire will include: * Patient satisfaction with their recovery process * Tolerability of the MCT diet * Any challenges experienced during the diet, including adherence and acceptability
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
Number of Participants with Symptoms Associated with MCT Diet
Patients will be monitored for any gastrointestinal discomfort associated with the MCT diet, including: * Diarrhea * Constipation * Bloating * Increased flatus Reports of these symptoms will be collected during the hospital stay and follow-up visits to assess the safety and tolerability of the MCT diet.
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
Number of patients with Infection symptoms
· Observing for symptoms such as fever or shortness of breath (SOB), which will be incorporated into the QoL questionnaire
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
Number of patients with infection risk
Regular checks for pleural-based complications, such as effusion, through chest X-rays (performed before discharge and during follow-ups)
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 22 interventional studies with no phase under Thoracic Neoplasms, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 3 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Nov 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →